Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved, pharmacological treatments with proven outcomes benefits in HFpEF have been elusive. Indeed, drug treatment still focuses on managing comorbidities, and first-line treatment typically consists of RAAS inhibitors, beta blockers, and diuretics. Also, unlike in heart failure patients with reduced ejection fraction (HFrEF), calcium channel blockers can be used in this subpopulation. Recently, Jardiance and Entresto secured FDA approval to treat HFpEF; these agents are already approved for HFrEF. This analysis provides insight into U.S. prescribing patterns for HFpEF.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, BiDil, Corlanor, Entresto
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.